FIELD: medicine.
SUBSTANCE: for bladder cancer treatment, effective amounts of apaziquone are administered intravesically. Administration is performed within 6 hours after bladder cancer transurethral resection.
EFFECT: reduced recurrence of surface bladder cancer due to pronounced cytostatic effect of the drug in the absence of systemic side effects.
14 cl, 1 tbl, 4 ex
Title | Year | Author | Number |
---|---|---|---|
INTRODUCTION OF APAZIQUONE INTRAVESICAL AFTER TRANSURETHRAL RESECTION IN CANCER TREATMENT | 2008 |
|
RU2480200C2 |
COMPOSITIONS AND METHODS OF TREATING BLADDER CANCER | 2008 |
|
RU2542449C2 |
METHOD OF TREATING BLADDER CANCER | 2014 |
|
RU2581946C2 |
METHODS OF TREATMENT OF TUMOR METASTASIS | 2018 |
|
RU2799546C2 |
METHOD OF COMPLEX TREATMENT AND PREVENTION OF RECURRENCES OF MUSCULAR-NON-INVASIVE FORMS OF URINARY BLADDER CANCER | 2013 |
|
RU2560314C2 |
METHOD OF TREATMENT OF SUPERFICIAL CANCER OF BLADDER | 2007 |
|
RU2350338C2 |
METHOD OF TREATING MALIGNANT BLADDER TUMOURS | 2009 |
|
RU2405601C1 |
METHOD FOR TREATING THE CASES OF URINARY BLADDER CANCER | 2005 |
|
RU2276605C1 |
METHOD FOR TREATMENT OF CANCER OF LOWER PATHWAY UROTHELIUM | 2017 |
|
RU2764747C2 |
METHOD OF PHOTODYNAMIC THERAPY (PDT) OF BLADDER CANCER | 2016 |
|
RU2745194C2 |
Authors
Dates
2017-06-22—Published
2012-12-26—Filed